Arterial Embolization News
-
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...
-
An Easy, Predictable, and Simpler Way to Embolize Tumors
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...
-
Reva medical announces closing of strategic financing
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. This funding was led by a global strategic investor with deep experience in medical devices, as well as BioStar Capital, and existing investors. Proceeds from the financing ...
-
Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluated[i] the ability of Embrace HES to ...
-
Synchron Appoints Kurt Haggstrom as Chief Commercial Officer
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. “I am honored and excited to join the Synchron team and be part of ...
-
SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
PARIS, France/Tampa, FL – July, 11, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately. Richardson has over 30 years of experience in the medical device industry, and an extensive ...
By SafeHeal
-
Rapid Medical Marks First Procedures with Numen Coil from MicroPort Scientific
Rapid Medical, a leading developer of advanced neurovascular devices, announces the expansion of its portfolio in the United States and the first Numen™ coil embolization procedure. Rapid Medical now has an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation. MircoPort’s global presence offers nearly 300 medical solutions to ...
-
Cordis-X Makes Strategic Investment in Adient Medical, Developer of First Fully Absorbable Inferior Vena Cava (IVC) Filter
Cordis-X today announced an $11.5 million Series F investment in Adient Medical, maker of a next-generation absorbable inferior vena cava (IVC) filter that provides protection against pulmonary embolisms (PE). The device is designed to avoid well-documented risks of perforation, migration, fracture, and thrombosis currently associated with IVC filters. Such safety issues have been the focus of ...
-
Reva Medical Presents 6-Month Results from Motiv BTK Pilot Study
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. Prof. Thomas Rand, MD from the Klinik Floridsdorf Vienna, Austria presented the initial ...
-
Okami Medical Announces FDA 510(k) Clearance of the LOBO-7 and LOBO-9 Vascular Occluders To Address A Wide Range Of Peripheral Embolization Cases
Aliso Viejo, CA – June 7, 2022 – Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company’s LOBO® Vascular Occlusion ...
-
Reva Medical Announces Final 5 Year Results for It’s Fantom II Coronary Scaffold Study
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications is pleased to announce exceptional 5 Year clinical results from its FANTOM II Study. The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United ...
-
Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). This prospective, single-arm ...
-
Axial3D and BIOMODEX Announce Strategic Partnership
Axial3D, an award-winning medical imaging technology company, headquartered in Belfast has announced a partnership with BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals. The partnership will enable Biomodex to speed the production of 3D-printed brain aneurysm models by reducing the time it takes to transform 2D medical images to 3D visuals. An ...
By Axial3D
-
InspireMD Announces Strong Second Quarter 2021 Financial Results
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the second quarter ended June 30, 2021. Second Quarter 2021 and recent highlights Revenue of $1,038,000 an increase of 231.6% compared to the same ...
-
Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patients in the Embrace Hydrogel Embolic System (HES™) global randomized clinical trial for the treatment of hypervascular tumors. As demonstrated previously in the completed First-in-Human (FIH) study, Embrace HES was ...
-
Performance Under Pressure: Studying Elite Free Divers with MediPines’ AGM100
A recent clinical study published by an international team of medical researchers from the University of British Columbia, Canada, and the University of Zagreb, Croatia, studied the extreme physiology of breath-hold free-divers. Published in this month’s Experimental Physiology, the study, entitled, “Temporal changes in pulmonary gas exchange efficiency when breath-hold diving below ...
By MediPines
-
Covid-19 respiratory monitoring with MediPines AGM100
MD Tech Review, a premier medical innovation magazine, has voted MediPines as a 2020 Top Ten Patient Monitoring Solution Provider. MediPines’ innovative respiratory technology, AGM100®, is making a positive impact in hospitals battling Covid-19. This industry recognition came about as MediPines introduced the AGM100®, an advanced respiratory monitoring system, commercially in the ...
By MediPines
-
Okami Medical Announces FDA 510(k) Clearance of the LOBO-5 Vascular Occluder
Aliso Viejo, CA- December 16, 2020 – Okami Medical Inc., a medical device company, today announced the expansion of its LOBO™ Vascular Occlusion System product line with the U.S. FDA 510(k) clearance of the LOBO-5 Vascular Occluder. The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, ...
-
Ground-breaking New Medical Device Saving Lives and Resources During Pandemic
A ground-breaking development in the detection of reduced lung function, as seen in COVID-19 patients, is saving lives, time, and resources. It’s thanks to the world’s first non-invasive lung function monitor, the MediPines AGM100®, developed in California, tested at University of British Columbia and Stevenson Memorial Hospital, and approved for use in Canada. Hospitals are ...
By MediPines
-
First Patients Enrolled in Balt STEM Trial
Balt announced today that the first patients have been enrolled in the clinical trial; The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic subdural hematoma [NCT04410146]. This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you